---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-130800"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:22:53.493374+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CG Oncology Phase 3 BOND-003: cretostimogene achieves 75.2% complete response in high-risk NMIBC

## Summary
- 75.2% complete response (79/105 patients; 95% CI: 65-83) at any time in BCG-unresponsive high-risk NMIBC.
- 29 patients maintained CR for ≥12 months; median duration of response not reached as of April 1, 2024.
- 92.4% cystectomy-free-survival; no CR patient had radical cystectomy or nodal/metastatic progression.
- No Grade 3+ TRAEs; 1.8% serious TRAEs (Grade 2 cystitis, clot retention); no treatment discontinuations.
- Topline data from fully enrolled Phase 3 BOND-003 expected by end of 2024.

## SEC filing metadata
- accession: 0001193125-24-130800
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312524130800/0001193125-24-130800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312524130800/d823423d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-130800
- JSON: https://secwatch.observer/filing/0001193125-24-130800.json
- Plain text: https://secwatch.observer/filing/0001193125-24-130800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.